September 11, 2024 Top Stocks For Smart Investment Choices
September 8, 2024 S&P 500 In Freefall: Is This The End Of The Bull Market?
September 6, 2024 Jobs Report Spotlight As Fed Weighs Rate Cut Decision
August 26, 2024 NVDA Earnings Report Insights
Amazon: Oracle Partnership Highlights Margin Expansion Potential
Nvidia: Why You Should Buy Before It Hits $145
Apple: Enough To Turn The Odds In Its Favor – Still Buy
AMD Is Coming For Nvidia’s AI Lead
Nvidia: Goldman Sachs’ Hilarious Downside Case
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
April 12, 2024 Improve Your Financial Status: A How-To Guide
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
Inovio Pharmaceuticals (INO) Stock Forecast for 2024, 2025, 2026. Sell or Buy?
Updated: September 13, 2024 (15:02)
Sector: HealthcareThe share price of Inovio Pharmaceuticals, Inc. (INO) now
Are you interested in Inovio Pharmaceuticals, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Inovio Pharmaceuticals stock price in 2024, 2025, 2026, 2027, 2028. How much will one Inovio Pharmaceuticals share be worth in 2024 - 2028?
When should I take profit in Inovio Pharmaceuticals stock? When should I record a loss on Inovio Pharmaceuticals stock? What are analysts' forecasts for Inovio Pharmaceuticals stock? What is the future of Inovio Pharmaceuticals stock? We forecast Inovio Pharmaceuticals stock performance using neural networks based on historical data on Inovio Pharmaceuticals stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Inovio Pharmaceuticals stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Inovio Pharmaceuticals shares. This happens once a day.
Historical and forecast chart of Inovio Pharmaceuticals stock
The chart below shows the historical price of Inovio Pharmaceuticals stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Inovio Pharmaceuticals stock price can be found in the table below.
Long-term forecasts by years.
Inovio Pharmaceuticals, Inc. a biotechnology company specializing in the discovery, development and commercialization of DNA drugs to treat, cure and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. Its SynCon immunotherapy design has the ability to disrupt the immune system’s tolerance to cancer cells and facilitate the cross-protection of strains against unrivaled and matched pathogens. The company participates in the conduct and planning of clinical trials of its DNA drugs for the treatment of HPV-associated cancers, including dysplasia of the cervix, vulva and anus; HPV-associated cancers, including cancers of the head and neck, cervix, anal canal, penis, vulva, and vagina; other HPV-associated diseases such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East respiratory syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and employees are ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., Bill & Melinda Gates Foundation, Epidemic Preparedness Innovation Coalition (EPIR), Defense Advanced Research Projects Agency (DARPA), Life Sciences GeneOne. HIV Vaccine Threat Reduction Forensic Network, Defense Consortium Medical Weapons Agency (GCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergic and Infectious Diseases, Life Science Plumb Line, Regeneron Pharmaceuticals, Roche / Genentech, University Pennsylvania, University. Walter Reed Army Research Institute and Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support the INO-4800 DNA research vaccine currently in Phase I of the COVID-19 clinical trials; and partnerships with the International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Inovio Pharmaceuticals daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Sep 15 | 6.76 | 6.53 | 7.00 | 7.14 |
| Sep 16 | 6.92 | 6.74 | 7.18 | 6.63 |
| Sep 17 | 6.66 | 6.46 | 6.78 | 4.95 |
| Sep 18 | 6.72 | 6.46 | 6.98 | 8.01 |
| Sep 19 | 7.04 | 6.87 | 7.28 | 5.94 |
| Sep 20 | 7.13 | 6.88 | 7.29 | 5.91 |
| Sep 21 | 7.25 | 7.12 | 7.42 | 4.28 |
| Sep 22 | 7.38 | 7.18 | 7.54 | 4.99 |
| Sep 23 | 7.63 | 7.34 | 7.78 | 6.03 |
| Sep 24 | 7.41 | 7.19 | 7.63 | 6.08 |
| Sep 25 | 7.52 | 7.30 | 7.75 | 6.07 |
| Sep 26 | 7.39 | 7.18 | 7.57 | 5.35 |
| Sep 27 | 7.32 | 7.13 | 7.41 | 3.90 |
| Sep 28 | 7.44 | 7.35 | 7.53 | 2.43 |
| Sep 29 | 7.61 | 7.51 | 7.70 | 2.53 |
| Sep 30 | 7.76 | 7.66 | 8.00 | 4.46 |
| Oct 01 | 7.71 | 7.53 | 7.86 | 4.30 |
| Oct 02 | 7.76 | 7.45 | 7.91 | 6.30 |
| Oct 03 | 7.91 | 7.69 | 8.02 | 4.22 |
| Oct 04 | 7.54 | 7.29 | 7.70 | 5.64 |
| Oct 05 | 7.62 | 7.37 | 7.92 | 7.39 |
| Oct 06 | 7.52 | 7.36 | 7.59 | 3.11 |
| Oct 07 | 7.87 | 7.75 | 8.16 | 5.28 |
| Oct 08 | 7.88 | 7.70 | 7.99 | 3.84 |
| Oct 09 | 8.03 | 7.87 | 8.21 | 4.39 |
| Oct 10 | 7.89 | 7.65 | 7.99 | 4.49 |
| Oct 11 | 7.78 | 7.57 | 7.99 | 5.60 |
| Oct 12 | 7.86 | 7.58 | 8.03 | 5.96 |
| Oct 13 | 7.97 | 7.69 | 8.24 | 7.20 |
| Oct 14 | 7.81 | 7.69 | 7.94 | 3.25 |
Inovio Pharmaceuticals Daily Price Targets
Inovio Pharmaceuticals Stock Forecast 09-15-2024.
Forecast target price for 09-15-2024: $6.76.
Positive dynamics for Inovio Pharmaceuticals shares will prevail with possible volatility of 6.663%.
Pessimistic target level: 6.53
Optimistic target level: 7.00
Inovio Pharmaceuticals Stock Forecast 09-16-2024.
Forecast target price for 09-16-2024: $6.92.
Positive dynamics for Inovio Pharmaceuticals shares will prevail with possible volatility of 6.214%.
Pessimistic target level: 6.74
Optimistic target level: 7.18
Inovio Pharmaceuticals Stock Forecast 09-17-2024.
Forecast target price for 09-17-2024: $6.66.
Negative dynamics for Inovio Pharmaceuticals shares will prevail with possible volatility of 4.713%.
Pessimistic target level: 6.46
Optimistic target level: 6.78
Inovio Pharmaceuticals Stock Forecast 09-18-2024.
Forecast target price for 09-18-2024: $6.72.
Positive dynamics for Inovio Pharmaceuticals shares will prevail with possible volatility of 7.415%.
Pessimistic target level: 6.46
Optimistic target level: 6.98
Inovio Pharmaceuticals Stock Forecast 09-19-2024.
Forecast target price for 09-19-2024: $7.04.
Positive dynamics for Inovio Pharmaceuticals shares will prevail with possible volatility of 5.609%.
Pessimistic target level: 6.87
Optimistic target level: 7.28
Inovio Pharmaceuticals Stock Forecast 09-20-2024.
Forecast target price for 09-20-2024: $7.13.
Positive dynamics for Inovio Pharmaceuticals shares will prevail with possible volatility of 5.577%.
Pessimistic target level: 6.88
Optimistic target level: 7.29
INO (INO) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Oct. | 6.73 | 6.36 | 6.89 | 7.62 |
| Nov. | 6.67 | 6.30 | 6.92 | 8.97 |
| Dec. | 6.45 | 6.07 | 6.70 | 9.43 |
Inovio Pharmaceuticals forecast for this year
Inovio Pharmaceuticals Stock Prediction for Oct 2024
An uptrend is forecast for this month with an optimal target price of $6.72685. Pessimistic: $6.36. Optimistic: $6.89
Inovio Pharmaceuticals Stock Prediction for Nov 2024
An downtrend is forecast for this month with an optimal target price of $6.67304. Pessimistic: $6.30. Optimistic: $6.92
Inovio Pharmaceuticals Stock Prediction for Dec 2024
An downtrend is forecast for this month with an optimal target price of $6.44615. Pessimistic: $6.07. Optimistic: $6.70
Inovio Pharmaceuticals (INO) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 6.10 | 5.96 | 6.24 | 4.40 |
| Feb | 5.54 | 5.28 | 5.89 | 10.25 |
| Mar | 5.50 | 5.17 | 5.79 | 10.64 |
| Apr | 6.04 | 5.73 | 6.24 | 8.22 |
| May | 6.14 | 5.94 | 6.56 | 9.46 |
| Jun | 6.35 | 5.90 | 6.67 | 11.52 |
| Jul | 6.23 | 5.74 | 6.47 | 11.36 |
| Aug | 6.36 | 6.15 | 6.85 | 10.22 |
| Sep | 6.54 | 6.22 | 6.83 | 9.00 |
| Oct | 7.01 | 6.55 | 7.39 | 11.37 |
| Nov | 7.11 | 6.76 | 7.31 | 7.49 |
| Dec | 7.72 | 7.55 | 8.16 | 7.38 |
Inovio Pharmaceuticals (INO) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 7.44 | 6.89 | 7.90 | 12.81 |
| Feb | 7.77 | 7.55 | 8.33 | 9.33 |
| Mar | 8.39 | 8.12 | 8.65 | 6.11 |
| Apr | 8.74 | 8.29 | 9.27 | 10.65 |
| May | 8.99 | 8.34 | 9.30 | 10.35 |
| Jun | 8.30 | 7.95 | 8.48 | 6.17 |
| Jul | 8.00 | 7.70 | 8.39 | 8.29 |
| Aug | 7.29 | 6.93 | 7.75 | 10.63 |
| Sep | 7.11 | 6.76 | 7.38 | 8.38 |
| Oct | 6.92 | 6.58 | 7.11 | 7.39 |
| Nov | 7.38 | 6.88 | 7.66 | 10.12 |
| Dec | 7.65 | 7.45 | 8.13 | 8.38 |
Inovio Pharmaceuticals information and performance
6769 MESA RIDGE RD., SAN DIEGO, CA, US
Market capitalization of the Inovio Pharmaceuticals, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of INO shares in the company outstanding by the market price of one share.
EBITDA of Inovio Pharmaceuticals is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
